olivLaw · US equity research
Embecta Corp. EMBC
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Embecta is a global medical device company focused on products for people with diabetes, including pen needles, syringes and safety devices sold in more than 100 countries. In 2026 it is undergoing a strategic shift after acquiring Owen Mumford, while US sales have fallen sharply and quarterly revenue remains under pressure from pricing and volume.
At the close of 04 Nov 2026, Embecta Corp. (EMBC) stock was 6.52 USD (+7.24% on the day), with market capitalisation 369.4 m USD, P/E 4.4 on diluted EPS of 1.47 USD over the last 12 months, dividend yield 7.06%, beta 0.86, 52-week range 2.90–14.64 USD. Latest reported quarter (Q3 2026): revenue of 271.7 m USD (−8.1% YoY), net income of 21.1 m USD (−53.6% YoY), diluted EPS 0.36 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.6
- strong (55–70)
- Bollinger (20, 2)
- 5.72 – 6.97
- in the upper half of the band · %B 0.64 · band width 19.7%
- SMA 50 / 200
- 5.81 / 6.43
- mixed trend
- MACD (12, 26, 9)
- 0.18 / 0.24
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +10.9% | −2.0% | +12.9 pp | — |
| 3 months | +82.6% | −2.2% | +84.8 pp | — |
| 6 months | +83.1% | +4.3% | +78.9 pp | — |
| Year to date | −45.1% | +10.6% | −55.7 pp | — |
| 1 year | −51.8% | +10.5% | −62.2 pp | −6.2% |
| 3 years | −59.8% | +73.7% | −133.4 pp | −18.1% |
| 5 years | unavailable | +61.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 286.1 m | 261.9 m | 259.0 m | 295.5 m | 264.0 m | 261.2 m | 221.8 m | 271.7 m |
| Cost of revenue | 112.3 m | 104.8 m | 94.9 m | 98.4 m | 105.5 m | 99.5 m | 94.0 m | 118.4 m |
| Gross profit | 173.8 m | 157.1 m | 164.1 m | 197.1 m | 158.5 m | 161.7 m | 127.8 m | 153.3 m |
| Research & development | 19.8 m | 20.3 m | 8.0 m | 4.4 m | 4.6 m | 4.6 m | 5.4 m | 5.6 m |
| SG&A | 96.8 m | 81.1 m | 79.6 m | 84.4 m | 86.9 m | 77.6 m | 76.2 m | 78.6 m |
| Operating income | 26.2 m | 28.7 m | 62.9 m | 94.0 m | 56.5 m | 83.3 m | 35.0 m | 48.7 m |
| Depreciation & amortisation | 9.5 m | 9.4 m | 9.0 m ≈ | 9.2 m ≈ | 13.1 m | 10.3 m | 10.2 m ≈ | 10.6 m ≈ |
| Pre-tax income | -7.0 m | -700.0 k | 35.8 m | 72.2 m | 29.0 m | 58.9 m | 9.5 m | 27.6 m |
| Income tax | -21.6 m | -700.0 k | 12.3 m | 26.7 m | 2.6 m | 14.8 m | 13.6 m | 6.5 m |
| Net income | 14.6 m | 0 | 23.5 m | 45.5 m | 26.4 m | 44.1 m | -4.1 m | 21.1 m |
| Diluted EPS | 0.25 ≈ | 0.00 | 0.40 | 0.78 | 0.44 ≈ | 0.74 | -0.07 | 0.36 |
| Operating cash flow | 26.6 m | -5.3 m | 31.8 m ≈ | 81.2 m ≈ | 84.0 m | 17.2 m | 31.1 m ≈ | 41.8 m ≈ |
| Capex | 0 | 1.5 m | 100.0 k ≈ | 400.0 k ≈ | 7.3 m | 600.0 k | 500.0 k ≈ | 1.1 m ≈ |
| Dividends paid | 8.7 m | 8.8 m | 8.7 m ≈ | 8.7 m ≈ | 8.8 m | 8.9 m | 8.9 m ≈ | 600.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 11 percentile of its own 18-quarter history (min 2.2, median 9.8, max 27.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.1 bn | 1.2 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.1 bn |
| Revenue YoY | unavailable | +7.4% | −3.1% | −0.8% | +0.2% | −3.8% |
| Net income | 427.6 m | 414.8 m | 223.6 m | 70.4 m | 78.3 m | 95.4 m |
| Net income YoY | unavailable | −3.0% | −46.1% | −68.5% | +11.2% | +21.8% |
| Diluted EPS | 7.50 | 7.28 | 3.89 | 1.22 | 1.34 | 1.62 |
| Diluted EPS YoY | unavailable | −2.9% | −46.6% | −68.6% | +9.8% | +20.9% |
| net % | 39.4% | 35.6% | 19.8% | 6.3% | 7.0% | 8.8% |
| Free cash flow | 456.6 m | 419.5 m | 388.6 m | 41.2 m | 19.9 m | 182.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Sept 2025
- Cash
- 225.5 m USD
- Financial debt
- 1.4 bn USD
- Net debt
- 1.2 bn USD
- Equity
- -650.6 m USD
- Total assets
- 1.1 bn USD
- Debt / equity
- unavailable
- Current ratio
- 2.41x
- ROE
- unavailable
- ROA
- 8.0%
- FCF margin
- 16.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.1 bn | 1.2 bn | 1.1 bn | 1.1 bn | 1.1 bn | 1.1 bn | SEC (XBRL)· 25 Nov 2025verified |
| Cost of revenue | 322.9 m | 364.9 m | 354.6 m | 370.9 m | 387.9 m | 403.6 m | SEC (XBRL)· 25 Nov 2025verified |
| Gross profit | 762.6 m | 800.4 m | 774.9 m | 749.9 m | 735.2 m | 676.8 m | SEC (XBRL)· 25 Nov 2025verified |
| Research & development | 61.4 m | 63.3 m | 66.9 m | 85.2 m | 78.8 m | 37.3 m | SEC (XBRL)· 25 Nov 2025verified |
| SG&A | 214.7 m | 240.3 m | 294.8 m | 341.3 m | 365.1 m | 332.0 m | SEC (XBRL)· 25 Nov 2025verified |
| Operating income | 486.5 m | 492.0 m | 309.6 m | 221.5 m | 166.8 m | 242.1 m | SEC (XBRL)· 25 Nov 2025verified |
| Depreciation & amortisation | 38.3 m | 38.3 m | 31.7 m | 32.6 m | 36.2 m | 40.7 m | SEC (XBRL)· 25 Nov 2025verified |
| EBITDA | 524.8 m ≈ | 530.3 m ≈ | 341.3 m ≈ | 254.1 m ≈ | 203.0 m ≈ | 282.8 m ≈ | SEC (XBRL)· 25 Nov 2025derived |
| Pre-tax income | 485.8 m | 494.9 m | 256.6 m | 105.7 m | 44.2 m | 136.3 m | SEC (XBRL)· 25 Nov 2025verified |
| Income tax | 58.2 m | 80.1 m | 33.0 m | 35.3 m | -34.1 m | 40.9 m | SEC (XBRL)· 25 Nov 2025verified |
| Net income | 427.6 m | 414.8 m | 223.6 m | 70.4 m | 78.3 m | 95.4 m | SEC (XBRL)· 25 Nov 2025verified |
| Diluted EPS | 7.50 | 7.28 | 3.89 | 1.22 | 1.34 | 1.62 | SEC (XBRL)· 25 Nov 2025verified |
| Weighted average diluted shares | 57.0 m | 57.0 m | 57.5 m | 57.8 m | 58.3 m | 58.9 m | SEC (XBRL)· 25 Nov 2025verified |
| Dividend per share | — | — | 0.15 | 0.60 | 0.60 | 0.60 | SEC (XBRL)· 25 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 0 | 0 | 330.9 m | 326.3 m | 267.5 m | 225.5 m | SEC (XBRL)· 25 Nov 2025verified |
| Receivables | — | 150.6 m | 22.2 m | 16.7 m | 193.0 m | 145.6 m | SEC (XBRL)· 25 Nov 2025verified |
| Inventories | — | 118.0 m | 122.8 m | 152.1 m | 171.5 m | 178.6 m | SEC (XBRL)· 25 Nov 2025verified |
| Current assets | — | 291.8 m | 664.7 m | 749.1 m | 761.0 m | 631.4 m | SEC (XBRL)· 25 Nov 2025verified |
| Property, plant & equipment, net | — | 451.0 m | — | — | — | — | SEC (XBRL)· 16 Mar 2022verified |
| Goodwill | — | 15.6 m | 15.7 m | 15.6 m | 15.6 m | 15.4 m | SEC (XBRL)· 25 Nov 2025verified |
| Intangibles (excl. goodwill) | — | 18.3 m | 8.9 m | 9.1 m | 8.1 m | 7.0 m | SEC (XBRL)· 07 Aug 2026verified |
| Total assets | — | 788.0 m | 1.1 bn | 1.2 bn | 1.3 bn | 1.1 bn | SEC (XBRL)· 25 Nov 2025verified |
| Accounts payable | — | 54.2 m | — | — | — | — | SEC (XBRL)· 16 Mar 2022verified |
| Short-term debt | — | 0 | 9.5 m | 9.5 m | 9.5 m | 9.5 m | SEC (XBRL)· 25 Nov 2025verified |
| Long-term debt | — | 0 | 1.6 bn | 1.6 bn | 1.6 bn | 1.4 bn | SEC (XBRL)· 25 Nov 2025verified |
| Current liabilities | — | 164.0 m | 301.0 m | 353.5 m | 374.0 m | 261.5 m | SEC (XBRL)· 25 Nov 2025verified |
| Equity | 572.2 m † | 594.3 m † | -891.4 m † | -821.7 m † | -738.3 m † | -650.6 m † | SEC (XBRL)· 25 Nov 2025verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 498.5 m | 456.3 m | 412.2 m | 67.7 m | 35.7 m | 191.7 m | SEC (XBRL)· 25 Nov 2025verified |
| Capex | 41.9 m | 36.8 m | 23.6 m | 26.5 m | 15.8 m | 9.3 m | SEC (XBRL)· 25 Nov 2025verified |
| Free cash flow | 456.6 m ≈ | 419.5 m ≈ | 388.6 m ≈ | 41.2 m ≈ | 19.9 m ≈ | 182.4 m ≈ | SEC (XBRL)· 25 Nov 2025derived |
| Investing cash flow | -41.9 m | -39.2 m | -24.0 m | -26.5 m | -15.8 m | -9.3 m | SEC (XBRL)· 25 Nov 2025verified |
| Financing cash flow | -456.6 m | -417.1 m | -48.0 m | -48.7 m | -73.4 m | -226.7 m | SEC (XBRL)· 25 Nov 2025verified |
| Dividends paid | 0 | 0 | 8.6 m | 34.4 m | 34.5 m | 35.0 m | SEC (XBRL)· 25 Nov 2025verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 65 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 369.4 m USD
Key indicators
Coverage and freshness
Score by group
- Valuation98
- Balance sheet33
- Quality84
- Growth0
- Returns100
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 7.88 – 67.93 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDA50.16 – 67.93 (Mid 59.05)10 companies used · median multiple 17.1x · quartiles 15.3x – 19.0xBAX, BDX, BSX, HAE, ICUI, MMM, PODD, RMD, SYK, WST
- Peers: P/E30.99 – 47.48 (Mid 42.18)10 companies used · median multiple 28.6x · quartiles 21.0x – 32.2xBSX, DXCM, GCTK, LMAT, MMM, PODD, RMD, SYK, UTMD, WST
- Dividend discount (DDM)7.88 – 10.60 (Mid 9.04)
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 65/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 8.6% | 69 (vs peers) | 8% |
| FCF conversion · Quality | 188.1% | 100 (on a fixed band) | 8% |
| Revenue CAGR 3Y · Growth | -1.5% | 0 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | -25.3% | 0 (on a fixed band) | 10% |
| Net debt / EBITDA · Balance sheet | 4.6x | 17 (vs peers) | 13% |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.7x | 73 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 4.4x | 93 (vs peers) | 13% |
| EV/EBITDA · Valuation | 6.0x | 100 (vs peers) | 13% |
| FCF yield · Valuation | 44.6% | 100 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | 7.4% | 100 (on a fixed band) | 8% |
| Payout ratio (FCF) · Returns | 16.5% | 100 (on a fixed band) | 5% |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet33/100 · 2/3 factors with a value
- Growth0/100 · 2/2 factors with a value
- Quality84/100 · 2/3 factors with a value
- Returns100/100 · 2/2 factors with a value
- Valuation98/100 · 3/3 factors with a value
Memo
EMBECTA CORP. (EMBC). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.1 bn USD in 2025; YoY growth -3.8%; net margin 8.6%; net debt/EBITDA 4.6x.
The estimated value range is 30.99–47.48 USD per share (median of 3 methods, agreement: low); assumptions are illustrative. Against the central value of 42.18 USD, the price of 6.52 USD leaves a potential of 547.0% (value / price − 1) and a margin of safety of 84.5% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 65/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF conversion: 188.1%
- Current ratio: 1.7x
- P/E (TTM): 4.4x
- EV/EBITDA: 6.0x
- FCF yield: 44.6%
- Shareholder yield (distributions): 7.4%
- Payout ratio (FCF): 16.5%
- The price is below the estimated value range
What contradicts it
- Revenue CAGR 3Y: -1.5%
- EPS CAGR 3Y: -25.3%
- Net debt / EBITDA: 4.6x
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): ROIC, Interest coverage.
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 118.2 bn | 33.1 | 16.0% | 13.8% | +11.2% | −16% / +5% |
| MMM3m Company | 91.5 bn | 26.4 | 80.8% | 14.0% | +1.5% | +3% / +114% |
| BSXBoston Scientific Corporation | 63.1 bn | 18.4 | 14.3% | 16.6% | +19.9% | −57% / −22% |
| BDXBecton, Dickinson And Company | 54.0 bn | 59.8 | 3.8% | 4.0% | +8.2% | +30% / +7% |
| RMDResMed Inc. | 31.9 bn | 20.7 | 26.4% | 27.8% | +9.9% | −11% / +44% |
| DXCMDexcom, Inc. | 30.9 bn | 32.7 | 37.7% | 19.4% | +15.6% | +31% / −28% |
| WSTWest Pharmaceutical Services, Inc. | 28.4 bn | 45.7 | 21.2% | 18.8% | +6.3% | +47% / +16% |
| GKOSGLAUKOS Corp | 14.6 bn | — | -22.8% | -24.6% | +32.3% | +132% / +286% |
| BAXBaxter International Inc. | 13.7 bn | — | -10.5% | -6.2% | +5.7% | +41% / −27% |
| PODDInsulet Corporation | 11.4 bn | 30.9 | 26.0% | 12.3% | +30.7% | −50% / −13% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| HAEHaemonetics Corporation | 5.8 bn | 62.3 | 11.2% | 7.1% | −2.0% | +57% / +58% |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| LMATLemaitre Vascular, Inc. | 2.0 bn | 30.9 | 16.8% | 25.0% | +13.5% | +6% / +67% |
| KMTSKestra Medical Technologies, Ltd. | 1.8 bn | — | -73.7% | -140.4% | +59.0% | +13% / unavailable |
| IARTIntegra Lifesciences Holdings Corp | 1.2 bn | 88.3 | 1.2% | 0.8% | +1.5% | +13% / −62% |
| SIBNSi-Bone, Inc. | 1.1 bn | — | -7.7% | -6.2% | +20.2% | +28% / +32% |
| MDXGMimedx Group, Inc. | 467.0 m | — | -8.5% | -6.3% | +20.0% | −53% / −59% |
| CARLCarlsmed, Inc. | 439.3 m | — | -6,196.9% | -57.4% | +85.9% | −1% / unavailable |
| BWAYBrainsway Ltd. | 439.0 m | 224.2 | 5.6% | 7.1% | +29.0% | +28% / +258% |
| OFIXOrthofix Medical Inc. | 395.9 m | — | -13.9% | -7.4% | +2.9% | −40% / −12% |
| EMBCEmbecta Corp. | 369.4 m | 4.4 | — | 8.6% | −3.8% | −52% / −60% |
| CTSOCytosorbents Corporation | 286.6 m | — | -336.2% | -48.9% | +4.1% | −72% / −81% |
| UTMDUtah Medical Products, Inc. | 230.6 m | 22.1 | 8.8% | 29.0% | −5.8% | +29% / −14% |
| LUNGPulmonx Corporation | 123.2 m | — | -90.3% | -47.9% | +8.0% | +75% / −74% |
1- and 3-year price returns: for EMBC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 3.80 Total return -36% · Per year -36% | 6.73 Total return 11% · Per year 11% | 10.17 Total return 65% · Per year 65% |
| 3 years | 3.26 Total return -35% · Per year -13% | 6.54 Total return 22% · Per year 7% | 10.90 Total return 94% · Per year 25% |
| 5 years | 2.79 Total return -34% · Per year -8% | 6.34 Total return 33% · Per year 6% | 11.68 Total return 126% · Per year 18% |
- Exit P/E± 1.63
- Net margin± 1.14
- Annual revenue growth± 1.00
- Annual dilution± 0.10
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Embecta is a global medical device company focused on products for people with diabetes, including pen needles, syringes and safety devices sold in more than 100 countries. In 2026 it is undergoing a strategic shift after acquiring Owen Mumford, while US sales have fallen sharply and quarterly revenue remains under pressure from pricing and volume.
SWOT
Strengths
- A recognized brand in diabetes management with a long history and a presence in more than one hundred countries.
- An intellectual property portfolio and an owned network of plants and distribution that support product quality.
- High gross margins compared with other medical device categories, partly sustained through product differentiation.
Weaknesses
- High dependence on a single product category, pen needles, which generates most of the revenue.
- Significant debt and credit agreement restrictions that limit financial flexibility.
- Falling US revenue and dependence on a few large customers reduce sales stability.
Opportunities
- Integrating Owen Mumford could open new revenue in drug delivery devices for pharmaceutical companies.
- Co-packaging partnerships with GLP-1 producers could extend pen needle use into new markets.
- Market-appropriate syringe launches and pending pen needle approvals could support a sales recovery.
Threats
- Once-weekly oral and injectable drugs could reduce demand for traditional injection devices.
- Price pressure from low-cost suppliers and group purchasing organizations could continue.
- Tariffs and buy-local measures could affect costs and access to foreign markets.
Risks
- Concentration in pen needleshigh
A large share of profits comes from one product; any drop in demand or prices could strongly affect results.
- Dependence on third-party suppliershigh
Components, notably cannulas supplied by BD, come from limited sources; an interruption could affect production.
- Indebtedness and credit restrictionsmedium
Existing debt and financial covenants could limit dividends and financing options.
- Owen Mumford integrationmedium
Integrating a large acquisition could delay synergies and divert management from the core business.
- Regulatory risksmedium
FDA and CE approvals for new products may take longer than expected and could delay launches.
Investment thesis
What would need to be true (bull case)
- If the Owen Mumford integration and new syringe and pen needle launches proceed as planned, the company could diversify revenue and reduce dependence on one category.
- Growth in international markets and GLP-1 B2B partnerships could offset the decline in the US.
- Cost reductions after restructuring and lower debt could improve margins and free cash flow.
What would break the thesis
- If the decline in US sales continues, revenue could stay under pressure even with the new acquisitions.
- New diabetes drugs could gradually reduce demand for pen needles, the company's main product.
- Debt and financial restrictions could limit the company's ability to invest and respond quickly to market changes.
What to watch
- Fourth quarter fiscal 2026 results and US revenue trendQ4 2026
- Progress of the Owen Mumford integration and its revenue contribution2027
- FDA and CE approvals for the new market-appropriate pen needles2027
- Fiscal 2027 guidance and debt reduction progressnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Embecta Corp. is a global medical device company focused on improving the health of people with diabetes. Its portfolio includes pen needles, insulin syringes and safety devices, many carrying brands with over a century of recognition, and was spun off from BD in 2022. The company sells mainly through wholesalers and distributors to retail and institutional channels, reaching users in over 100 countries from three plants in Ireland, the United States and China.
According to the annual report, the company went through restructuring: it discontinued its patch pump program and streamlined the organization to focus on its core business. In May 2026 it completed the Owen Mumford acquisition, extending its activity toward drug delivery devices for pharmaceutical companies and chronic care, including obesity and anaphylaxis.
Operational efficiency, intellectual property and the global distribution network remain the pillars of the business model, while the cost structure and debt level limit short-term financial flexibility.
Segments
Pen needles
This is the main product, accounting for approximately 73% of total net revenues in fiscal 2025. In the first nine months of fiscal 2026, pen needle sales declined, showing the company's dependence on this category 12.
Syringes and safety devices
Insulin syringes and safety devices are smaller categories with more stable trends. In the third quarter of fiscal 2026 syringes grew slightly and safety devices grew moderately, which could offset part of the pen needle decline 3.
Market context
The diabetes device market is highly competitive and sensitive to innovation, with new products appearing often. Price pressure comes from lower-cost suppliers, volume-based purchasing and group purchasing organizations, while once-weekly oral and injectable drugs reduce demand for traditional injection devices 1.
Revenue in the US fell by about a quarter in the third quarter of fiscal 2026, while international markets grew, showing a sharp geographic split in demand 3.
Trends
- Price pressure and commoditizationheadwind
Lower-cost competitors and volume purchasing reduce prices and margins, while syringes and pen needles become more commoditized, especially in emerging markets 2.
- New diabetes drugsheadwind
Once-weekly oral and injectable drugs such as GLP-1 delay the start of insulin therapy and reduce demand for the company's products 12.
- B2B partnerships for GLP-1tailwind
The launch of generic GLP-1 therapies co-packaged with pen needles in Canada and Brazil shows a co-packaging opportunity with industry partners 3.
- Tariffs and global trademixed
US tariffs and foreign government responses could raise costs and favor local manufacturers, affecting margins and distribution 12.
Competitive position
The company competes with large firms that have multiple product lines, smaller specialized companies and new entrants from technology. The annual report names Novo Nordisk, MTD Group and Terumo Medical Corporation as competitors in diabetes drug injection 1.
Competition in the pen needle category is intensified by regional suppliers with low costs, which could affect pricing and market share if distributors shift preferences 2.
- Novo NordiskNVO
Pharmaceutical company named in the report as a competitor in diabetes injection.
- MTD Group
Company named in the report as a competitor in the diabetes injection segment.
- Terumo Medical Corporation
Medical device maker named as a competitor in insulin administration.
- Regional low-cost suppliers
Local and regional manufacturers offering cheaper needles and syringes, especially in emerging markets.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report07 Aug 2026
- Current report07 Aug 2026Results of operations · Financial statements and exhibits
- Current report (amendment)31 Jul 2026Financial statements and exhibits
- Current report15 May 2026Acquisition or disposition of assets · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report05 May 2026
- Current report05 May 2026Results of operations · Financial statements and exhibits
- Current report20 Mar 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Current report13 Feb 2026Shareholder vote
- Quarterly report05 Feb 2026
- Current report05 Feb 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-09-30 · SEC / Embecta Corp. · 25 Nov 2025
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Embecta Corp. · 07 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Embecta Corp. · 07 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.